An anticoagulant peptide from Porphyra yezoensis inhibits the activity of factor XIIa: In vitro and in silico analysis

Syed, Azeemullah A.; Venkatraman, Kalkooru L.; Mehta, Alka

doi:10.1016/j.jmgm.2019.03.019

Cited by 10 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MM/PBSA method calculated the drug's target-protein receptor binding free energy. Molecular mechanics potential energy (electrostatic and van der Waals interaction) and free energy of solvation (polar and nonpolar solvation energies) are used to estimate binding energy from dynamic trajectories [57].…”

Section: In Silico Studymentioning

confidence: 99%

A Deep Overview of Anticoagulant Drugs: Recent Synthesis and Their Activity Assay

Astuti,

Ibrahim,

Zulfikar

et al. 2024

Indones. J. Chem.

View full text Add to dashboard Cite

During the unprecedented COVID-19 pandemic, anticoagulant drugs have emerged as a crucial component of treatment alongside antivirus medications. Patients with severe COVID-19 frequently have critical conditions marked by blood clot development, necessitating the administration of anticoagulants. This review aims to provide a comprehensive overview of various anticoagulant drugs, their synthesis methods, and assays employed to predict their anticoagulant activity. Notable anticoagulant categories frequently utilized include oral anticoagulants heparin, non-vitamin K antagonists, and vitamin K antagonists. In recent years, the development of new anticoagulants has seen a shift towards a multifaceted approach that combines in silico prediction with in vitro and in vivo assays. In silico prediction techniques play a pivotal role in the initial screening process. This integrated approach has yielded promising results, paving the way for the synthesis of novel anticoagulant candidates, as substantiated by a battery of in vitro, in vivo, and ex-vivo tests.

show abstract

Section: In Silico Studymentioning

confidence: 99%

A Deep Overview of Anticoagulant Drugs: Recent Synthesis and Their Activity Assay

Astuti,

Ibrahim,

Zulfikar

et al. 2024

Indones. J. Chem.

View full text Add to dashboard Cite

show abstract

“…yezoensis (NMEKGSSSVVSSRMKQ) and the coagulation factor XIIa. The study reported that interactions of this peptide with factor XIIa were through hydrogen bonds [113]. Molecular docking of peptides derived from U. intestinalis , FGMPLDR, and MELVLR, indicated that these peptides were able to bind to the active site of ACE through a network of hydrogen bonds and hydrophobic and Van der Waals interactions, and that glycine (G) and Leucine (L) residues within the peptides disturb the Zn(II) ion within ACE potentially resulting in inhibition of the enzyme activity [103].…”

Section: In Silico Analysismentioning

confidence: 99%

Current knowledge on the extraction, purification, identification, and validation of bioactive peptides from seaweed

et al. 2020

View full text Add to dashboard Cite

Current knowledge on the extraction, purification, identification, and validation of bioactive peptides from seaweed Seaweed (macroalgae) is considered as a sustainable bioresource rich in high-quality nutrients such as protein. Seaweed protein can be used as an alternative to other protein sources. Furthermore, these proteins are natural reservoirs of bioactive peptides (BAPs) associated with various health benefits such as antioxidant, antihypertensive, and antidiabetic activities. However, seaweed-derived BAPs remain underexploited due to challenges that arise during protein extraction from algal biomass. Coupled with this, limited proteomic information exists regarding certain seaweed species. This review highlights the current state of the art of seaweed protein extraction techniques, e.g., liquid, ultrasound, microwave, pulsed electric field, and high hydrostatic pressure assisted extraction. The review also focuses on the enzymatic hydrolysis of seaweed proteins and characterization of the resultant hydrolysates/peptides using electrophoretic and chromatographic techniques. This includes reference to methods employed for separation, fractionation, and purification of seaweed BAPs, as well as the methodologies used for identification, e.g., analysis by mass spectrometry. Furthermore, a bioinformatics or in silico approach to aid discovery of seaweed BAPs is discussed herein. Based on the information available to date, it is suggested that further research is required in this area for the development of seaweed BAPs for nutraceutical applications.

show abstract

“…Marine products generally exhibit particular scaffolds not found in terrestrial sources [168,169]. From the hydrolysate of marine organisms, two FXIIa inhibitors were reported: the 12-kDa yellowfin sole anticoagulant protein [170] and the 16-mer peptide VITPOR AI (IC50 in plasma = 70.24 µM) [171,172].…”

Section: Discovery From Marine Organismsmentioning

confidence: 99%

Factor XII/XIIa inhibitors: Their discovery, development, and potential indications

Davoine

Bouckaert

Fillet

et al. 2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

An anticoagulant peptide from Porphyra yezoensis inhibits the activity of factor XIIa: In vitro and in silico analysis

Cited by 10 publications

References 45 publications

A Deep Overview of Anticoagulant Drugs: Recent Synthesis and Their Activity Assay

A Deep Overview of Anticoagulant Drugs: Recent Synthesis and Their Activity Assay

Current knowledge on the extraction, purification, identification, and validation of bioactive peptides from seaweed

Factor XII/XIIa inhibitors: Their discovery, development, and potential indications

Contact Info

Product

Resources

About